Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy - a randomised trial (RAACENO)

niversity of Aberdeen and NHS Grampian0 个研究点目标入组 515 人开始时间: 2017年4月12日最近更新: 2024年6月10日

适应症

试验速览

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31585544 protocol (added 07/10/2019) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35101183/ (added 02/02/2022) 2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/36603013/ Qualitative process evaluation (added 07/06/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35679443/ (added 07/06/2023) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38802171/ Cost analysis (added 28/05/2024)

•1. Asthma diagnosed or confirmed by consultant paediatrician (or Read code for asthma if recruited in primary care)
•2. Aged 6 years or older and not yet reached the date of their 16th birthday
•3. Currently prescribed inhaled corticosteroids (<1000mcg budesonide equivalent per day in those <12 years; <2000 mcg budesonide equivalent per day for older children)
•4. At least one patient/parent reported-asthma exacerbation treated with oral corticosteroids in the 12 months prior to recruitment

•1. Unable to provide FeNO measurement at baseline assessment (expected prevalence <5%)
•2. Other chronic respiratory conditions which also have exacerbations
•3. Current treatment with maintenance oral steroids

发起方

niversity of Aberdeen and NHS Grampian